
Sign up to save your podcasts
Or


As competitors publicly entered the race to produce a vaccine, drug giant Merck stayed quiet about its development plans. Now, the company has revealed it’s working on two vaccines and a treatment pill -- emerging as a frontrunner in the development contest. Although the company has refused to give firm timelines for its research, it has pledged to make its vaccines and pill available globally, if they're successful. Riley Griffin talked with Merck Chief Executive Kenneth C. Frazier about the company's plans.
See omnystudio.com/listener for privacy information.
By Bloomberg3.7
805805 ratings
As competitors publicly entered the race to produce a vaccine, drug giant Merck stayed quiet about its development plans. Now, the company has revealed it’s working on two vaccines and a treatment pill -- emerging as a frontrunner in the development contest. Although the company has refused to give firm timelines for its research, it has pledged to make its vaccines and pill available globally, if they're successful. Riley Griffin talked with Merck Chief Executive Kenneth C. Frazier about the company's plans.
See omnystudio.com/listener for privacy information.

78,613 Listeners

32,196 Listeners

6,801 Listeners

29,047 Listeners

15,457 Listeners

2,690 Listeners

403 Listeners

2,179 Listeners

1,971 Listeners

423 Listeners

12,119 Listeners

17,803 Listeners

969 Listeners

112,664 Listeners

194 Listeners

30 Listeners

10,051 Listeners

4 Listeners

58 Listeners

233 Listeners

228 Listeners

65 Listeners

77 Listeners

82 Listeners

394 Listeners

18 Listeners

12 Listeners

7 Listeners

2 Listeners

72 Listeners

1,151 Listeners

186 Listeners